

## **P19. IMMUNOSUPPRESSIVE TREATMENT IN APLASTIC ANEMIA-EXPERIENCE OF HEMATOLOGY DEPARTMENT OF IOCN.**

***C.Tomescu<sup>1</sup>,L.Urian<sup>1</sup>,A.Bojan<sup>1</sup>,L.Petrov<sup>2</sup>***

**1" Iuliu Hațieganu" University of Medicine and Pharmacy, Hematology Department of IOCN**

**2" Ion Chiricuță" Cancer Institute, Hematology Department**

**Background.** Aplastic anemia is a clonal disease of stem cell characterized by peripheral blood pancytopenia with hypocellular bone marrow. In most cases, acquired aplastic anemia is an autoimmune, T-cell mediated disease.

**Material and methods.** We have enrolled in the study all the patients which were diagnosed with aplastic anemia, during their admission in the Hematology Department of "Ion Chiricuța" Cancer Institute Cluj Napoca, between 2004-2014. We have analyzed the next parameters: the age, gender, clinical manifestation of the disease, haemogram, bone marrow biopsy, kind of treatment, answer of treatment, adverse events and evolution of patients.

**Results.** The studied group was formed by 85 patients. The average age for the investigated patients was 46 years and there were 47 women and 38 men. The treatment consisted in ATG in 28 patients and CSA in 34 patients, with the response rate of 70%.

**Conclusion.** The response rate in this study is good, correlate with young age, absolute reticulocyte and lymphocyte count.